ClinicalTrials.gg
Active, not recruitingNCT04565925Updated Sep 9, 2026

Sildenafil for Treatment of Urinary Incontinence in Patients With Spinal Cord Injuries

A Phase 2 interventional study of Sildenafil Citrate and Placebo in Spinal Cord Injuries and Urinary Incontinence, sponsored by The University of Texas Medical Branch, Galveston. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by The University of Texas Medical Branch, Galveston · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 968 studies in Spinal Cord Injuries with a site in United States — 249 open to participants now, 308 under way, 7 of them phase 3. Spinal Cord Injuries · United States.

Planned enrollment
399th of 836
24 · median 24
Started
2021
with 57 others
Phase 2
77 of 968
6 open now
Primary completion
2026-12
later than 90 of 307 live
Registered
603rd of 968
by date

Among the 968 studies in Spinal Cord Injuries with a site in United States, this one is the 399th largest by planned enrollment of the 836 interventional ones that give a count, is one of 58 that started in 2021, is one of 77 in phase 2, reaches primary completion later than 90 of the 307 other live ones, and was the 603rd registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

249 of the 968 studies in Spinal Cord Injuries with a site in United States are open now. Recruiting first, the newest first:

244 more — sign in →

All 249 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 968 studies in Spinal Cord Injuries with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to determine whether administration of sildenafil will decrease urine leakage in patients with spinal cord injuries.

Read the detailed description

Spinal cord injury (SCI) is a devastating condition affecting 291,000 women and men in the US alone. Urinary incontinence (UI) is a common problem in these patients, affecting 52% of the population, with episodes of incontinence occurring daily in 20-27% of affected persons. UI after spinal cord injury (SCI) is a major cause of distress and morbidity amongst patients with SCI, and is associated with decreased quality of life in general, physical, and emotional domains. UI has the undesirable side effects of perineal irritation and infection, increased odor, disrupted sleep, embarrassment, need to change clothes/bedding, and sexual dysfunction, as well as significant financial burden. Persons living with a SCI have ranked urinary problems as the most important health problem after injury. Addressing this significant problem and providing relief has the potential to significantly improve the lives of patients with SCI.

Typical treatment options are geared toward the type of UI in each patient. For stress UI, the goal of treatment is to provide support to the pelvic floor and urethra. Pessaries (devices placed inside the vagina in women) or surgery (e.g. suburethral sling) to elevate the urethra and/or bladder neck to increase the resistance to leak through the urethra are commonly used. Urethral bulking agents or pelvic muscle floor therapy are also employed to strengthen the closure pressure of the urethra in patients with stress UI. No pharmacologic agents are currently available to treat stress UI. For urge UI, medications or electrical stimulation aimed at relaxation of the detrusor muscle, including anticholinergics, are used. For overflow or obstructive UI, treatments are aimed at shrinking or removing the obstruction, such as medications to shrink the prostate, prostatectomy or mass removal. For neurogenic UI, surgery for diversion or implant placement may be utilized.

Sildenafil (Viagra) has been well studied and used extensively in males to treat erectile dysfunction. Phosphodiesterase 5 (PDE5) inhibitors, including sildenafil, are potent vasodilators that enhance tissue perfusion, relax smooth muscle of the vasculature and bladder, and stimulate skeletal muscle protein synthesis. It has been reported to improve lower urinary tract symptoms, including urge UI and benign prostatic hyperplasia (BPH) in men. In our team's recent study using sildenafil for treatment of UI in women, the investigators found improvement in quality of life and a decrease in the number of incontinence episodes in women taking sildenafil. Higher sildenafil plasma levels were associated with greater improvement in symptoms. While the types of UI in women are somewhat different than in men, studies have shown improvements in UI in both sexes.

Thus, the investigators propose to conduct a two month randomized, placebo-controlled crossover trial of sildenafil in male and female adult SCI patients with UI to assess the therapeutic potential of sildenafil to reduce the symptoms of urinary leakage.

Aims:

Aim 1: To determine whether sildenafil will decrease episodes of leakage of UI in adult women and men with SCI.

Aim 2: To determine the effects of sildenafil on the subjective measures of UI, including quality of life.

Experimental Protocol:

Investigators will study patients with spinal cord injuries (aged 18-70) with current urine leakage of more than 3 times/week (n=24). Subjects will undergo a double blinded randomized cross over treatment of sildenafil (20mg TID) and placebo. Each treatment period will last 4 weeks with a 2 week washout between treatment periods.

Before and after each treatment period, subjects will undergo testing which will consist of measurements of urine post void residual volume (PVR), adverse event assessment, and questionnaires of quality of life and urinary health.

03

Conditions studied

  • Spinal Cord Injuries
  • Urinary Incontinence
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults with spinal cord injury (SCI), 18-75 years of age, at the time of consent
  • Have urinary incontinence (UI), with at least 3 leakage episodes/week
  • Have urodynamics assessment on file with their provider in past 3 years. If no historical data on file, subject may complete prior to study visit 1.
  • Willing and able to comply with study procedures
  • Willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  • In phone prescreen, delighted or pleased with current quality of life due to urinary symptoms.
  • Indwelling catheter
  • History of greater than 4 urinary tract infections per year
  • Multiple sclerosis
  • Significant heart, liver, kidney, pulmonary, blood, or peripheral vascular disease
  • Systolic blood pressure \<90 or >170, diastolic blood pressure \<50 or >110 after repeated evaluation with proper cuff. This range is the acceptable range stated in the prescribing information for sildenafil (>90/50 and \<170/110)
  • Active cancer
  • , , or
  • Use of systemic nitrates, anabolic steroids, , or long acting PDE5 inhibitors in the past 1 month
  • Use of short acting PDE5 inhibitors in the past 1 week
  • Use of alpha blockers, anticholinergic agents, bethanechol, or other UI treatment within the past 2 weeks ( 3 weeks for long acting muscarinic receptor antagonists)
  • Known allergic reaction to any agent under investigation or required by the protocol
  • Females who are pregnant or lactating
  • Atonic bladder or high detrusor and high pelvic floor muscle pressure based on previous cystometrogram (CMG) (on file with their provider) that would place subjects at risk for kidney injury
  • Any medical condition that, in the opinion of the investigator, would place the subject at increased risk for participation
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Sildenafil 20mg TID then Placebo TID

    Subjects will be administered Sildenafil 20mg TID for 4 weeks. There will be a 2 week washout period then subjects will be administered Placebo (lactose) TID for 4 weeks.

    Drug: Sildenafil Citrate · Drug: Placebo

  • Experimental
    Placebo TID then Sildenafil 20mg TID

    Subjects will be administered Placebo (lactose) TID for 4 week. There will be a 2 week washout period and then subjects will be administered Sildenafil 20mg TID for 4 weeks.

    Drug: Sildenafil Citrate · Drug: Placebo

Interventions

  • DrugSildenafilStudies of SildenafilSildenafil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Sildenafil 20mg TID for 4 weeks

    Also known as: Revatio

  • DrugPlacebo

    Placebo (Lactose) TID for 4 weeks

    Also known as: Lactose

06

What researchers measure

Primary outcomes

  1. Bladder Leakage as measured by 5 day bladder diary at Baseline

    Bladder leakage will be measured by bladder diary, which will be kept for five- 24 hours periods at baseline. Subjects will be asked to record the number of leaks each day. Data will be calculated by summing total number of leaks over the 5 day recording period and dividing the sum by 5, resulting in average leaks per day.

    Time frame: baseline

  2. Bladder Leakage as measured by 5 day bladder diary after 4 weeks of Sildenafil Treatment

    Bladder leakage will be measured by bladder diary, which will be kept for five 24 hours periods in the last week of the 4 weeks of sildenafil treatment.

    Time frame: after 4 weeks of sildenafil treatment

  3. Bladder Leakage as measured by 5 day bladder diary after 4 weeks of Placebo Treatment

    Bladder leakage will be measured by bladder diary, which will be kept for five 24 hours periods in the last week of the 4 weeks of placebo treatment.

    Time frame: after 4 weeks of placebo treatment

Secondary outcomes

  1. Blood sildenafil levels as measured by Liquid Chromatography Mass Spectrometry (LCMS) at baseline

    Sildenafil levels will be measured in plasma samples taken at baseline using a Liquid Chromatography Mass Spectrometry-Mass Spectrometry (LCMS-MS) method. Data will be reported as ng/ml.

    Time frame: baseline

  2. Blood sildenafil levels as measured by Liquid Chromatography Mass Spectrometry (LCMS) after 4 weeks of sildenafil treatment

    Sildenafil levels will be measured in plasma samples taken after 4 weeks of sildenafil treatment using a Liquid Chromatography Mass Spectrometry-Mass Spectrometry (LCMS-MS) method. Data will be reported as ng/ml.

    Time frame: after 4 weeks of sildenafil treatment

  3. Blood sildenafil levels as measured by Liquid Chromatography Mass Spectrometry (LCMS) after 4 weeks of placebo treatment

    Sildenafil levels will be measured in plasma samples taken after 4 weeks of placebo treatment using a Liquid Chromatography Mass Spectrometry-Mass Spectrometry (LCMS-MS) method. Data will be reported as ng/ml.

    Time frame: after 4 weeks of placebo treatment

  4. Post void residual urine volume as measured by ultrasound bladder scanner at baseline

    Post void residual urine volume is measured using an ultrasound bladder scanner. To perform this test, the research subject empties their bladder and then the bladder scanner is used to measure any remaining urine in the bladder. Results will be reported as mL urine remaining.

    Time frame: baseline

  5. Post void residual urine volume as measured by ultrasound bladder scanner after 4 weeks of sildenafil treatment

    Post void residual urine volume is measured using an ultrasound bladder scanner. To perform this test, the research subject empties their bladder and then the bladder scanner is used to measure any remaining urine in the bladder. Results will be reported as mL urine remaining.

    Time frame: after 4 weeks of sildenafil treatment

  6. Post void residual urine volume as measured by ultrasound bladder scanner after 4 weeks of placebo treatment

    Post void residual urine volume is measured using an ultrasound bladder scanner. To perform this test, the research subject empties their bladder and then the bladder scanner is used to measure any remaining urine in the bladder. Results will be reported as mL urine remaining.

    Time frame: after 4 weeks of placebo treatment

  7. Urinary symptoms as measured by the American Urological Association Symptom Score at baseline

    Urinary symptoms will be assessed using the American Urological Association (AUA) Symptom Score, a 7 item questionnaire that assess how bothersome urinary problems are and if treatment is effective. The AUA symptom score yields one overall score (range 0 - 35, with higher scores indicating higher severity). Total scores of 0-7 mild symptoms; 8-19 moderate symptoms; 20-35 severe symptoms

    Time frame: baseline

  8. Urinary symptoms as measured by the American Urological Association Symptom Score after 4 weeks of sildenafil treatment

    Urinary symptoms will be assessed using the American Urological Association (AUA) Symptom Score, a 7 item questionnaire that assess how bothersome urinary problems are and if treatment is effective. The AUA symptom score yields one overall score (range 0 - 35, with higher scores indicating higher severity). Total scores of 0-7 mild symptoms; 8-19 moderate symptoms; 20-35 severe symptoms

    Time frame: after 4 weeks of sildenafil treatment

  9. Urinary symptoms as measured by the American Urological Association Symptom Score after 4 weeks of placebo treatment

    Urinary symptoms will be assessed using the American Urological Association (AUA) Symptom Score, a 7 item questionnaire that assess how bothersome urinary problems are and if treatment is effective. The AUA symptom score yields one overall score (range 0 - 35, with higher scores indicating higher severity). Total scores of 0-7 mild symptoms; 8-19 moderate symptoms; 20-35 severe symptoms

    Time frame: after 4 weeks of placebo treatment

  10. Bladder dysfunction as measured by the Neurogenic Bladder Symptom Score at baseline

    The Neurogenic Bladder Symptom Score (NBSS) is a validated questionnaire that assess symptoms of bladder dysfunction due to spinal cord injury. Three distinct domains are assessed: incontinence; storage and voiding; and consequences. Scores can range from 0 (no symptoms at all) to 74 (maximum symptoms).

    Time frame: baseline

  11. Bladder dysfunction as measured by the Neurogenic Bladder Symptom Score after 4 weeks of sildenafil treatment

    The Neurogenic Bladder Symptom Score (NBSS) is a validated questionnaire that assess symptoms of bladder dysfunction due to spinal cord injury. Three distinct domains are assessed: incontinence; storage and voiding; and consequences. Scores can range from 0 (no symptoms at all) to 74 (maximum symptoms).

    Time frame: after 4 weeks of sildenafil treatment

  12. Bladder dysfunction as measured by the Neurogenic Bladder Symptom Score after 4 weeks of placebo treatment

    The Neurogenic Bladder Symptom Score (NBSS) is a validated questionnaire that assess symptoms of bladder dysfunction due to spinal cord injury. Three distinct domains are assessed: incontinence; storage and voiding; and consequences. Scores can range from 0 (no symptoms at all) to 74 (maximum symptoms).

    Time frame: after 4 weeks of placebo treatment

  13. Perception of bladder conditions as measured by the Patient Perception of Bladder Symptoms questionnaire at baseline

    The Patient Perceived Bladder Condition (PPBC) is a one item assessment measuring the severity of bladder problems with a likert scale with a range from 1 (best) to 6 (worst).

    Time frame: baseline

  14. Perception of bladder conditions as measured by the Patient Perception of Bladder Symptoms questionnaire after 4 weeks of sildenafil treatment

    The Patient Perceived Bladder Condition (PPBC) is a one item assessment measuring the severity of bladder problems with a likert scale with a range from 1 (best) to 6 (worst).

    Time frame: after 4 weeks of sildenafil treatment

  15. Perception of bladder conditions as measured by the Patient Perception of Bladder Symptoms questionnaire after 4 weeks of placebo treatment

    The Patient Perceived Bladder Condition (PPBC) is a one item assessment measuring the severity of bladder problems with a likert scale with a range from 1 (best) to 6 (worst).

    Time frame: after 4 weeks of placebo treatment

  16. Urinary Symptoms Interference as measured by Pelvic Floor Impact Questionnaire at baseline

    Pelvic Floor Impact Questionnaire (PFIQ-7) is a 7 item questionnaire measuring how much urinary symptoms affect activities of daily living, relationships and feelings. Each question is answered three times each, corresponding to the three scales - bladder/urine; bowel/rectum; vagina/penis). Responses for each question range from "not at all" (0) to "quite a bit" (3). Each scale is scored separately by calculating the mean of all seven questions and multiplying that number by 100 and then dividing by 3. Scale scores range from 0-100 with lower scores indicating less effect on quality of life. PFIQ-7 summary score is calculated by summing all three subscale scores (range 0-300).

    Time frame: baseline

  17. Urinary Symptoms Interference as measured by Pelvic Floor Impact Questionnaire after 4 weeks of sildenafil treatment

    Pelvic Floor Impact Questionnaire (PFIQ-7) is a 7 item questionnaire measuring how much urinary symptoms affect activities of daily living, relationships and feelings. Each question is answered three times each, corresponding to the three scales - bladder/urine; bowel/rectum; vagina/penis). Responses for each question range from "not at all" (0) to "quite a bit" (3). Each scale is scored separately by calculating the mean of all seven questions and multiplying that number by 100 and then dividing by 3. Scale scores range from 0-100 with lower scores indicating less effect on quality of life. PFIQ-7 summary score is calculated by summing all three subscale scores (range 0-300).

    Time frame: after 4 weeks of sildenafil treatment

  18. Urinary Symptoms Interference as measured by Pelvic Floor Impact Questionnaire after 4 weeks of placebo treatment

    Pelvic Floor Impact Questionnaire (PFIQ-7) is a 7 item questionnaire measuring how much urinary symptoms affect activities of daily living, relationships and feelings. Each question is answered three times each, corresponding to the three scales - bladder/urine; bowel/rectum; vagina/penis). Responses for each question range from "not at all" (0) to "quite a bit" (3). Each scale is scored separately by calculating the mean of all seven questions and multiplying that number by 100 and then dividing by 3. Scale scores range from 0-100 with lower scores indicating less effect on quality of life. PFIQ-7 summary score is calculated by summing all three subscale scores (range 0-300).

    Time frame: after 4 weeks of placebo treatment

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Dec 2026, 64 months after the start.

Of 44 non-industry phase 2 interventional studies under Spinal Cord Injuries, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 64. This study's planned 64 months is above that.

Counting every sponsor, half of 49 studies reached it within 46 months; a quarter within 28 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2020
First posted
Sep 25, 2020
StartActual
Jul 7, 2021
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04565925
Responsible party
Sponsor
First posted
Sep 25, 2020
Start date
Jul 7, 2021
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Sep 9, 2026

Study contacts

Kathy Vincent, MD
principal investigator · University of Texas

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion